Emyria Receives $2.5M R&D Tax Incentive Refund
Filed with ASX · · 2 pages · English
Story so far
Earlier from Emyria
- Emyria Specialist Granted Authorised Prescriber Status
- Board Changes and Executive Restructuring
- Emyria Secures Ethics Endorsement for MDMA AP Application
- Emyria hails strong growth in clinical billings
- September 2023 Quarterly Activities Report and Appendix 4C
Later from Emyria
- December 2023 Quarterly Activities Report and Appendix 4C
- Response to ASX Aware Query
- Emyria, Reach Wellness Enter MDMA-AT Research Agreement
- Emyria Expands Specialist AP Team - First Female for MDMA-AT
- Emyria Opens Empax Centre to Advance Mental Health Care
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria